eli lilly phase 3 trial retatrutide Who Makes Retatrutide? Company Behind the Weight Loss Drug Eli Lilly Experimental Drug Shows

Chronic caffeine treatment protects against -synucleinopathy by reestablishing autophagy activity in the mouse striatum

These forward-looking statements speak only as of the date hereof

The trial enrolled 445 adults with obesity and moderate-to-severe knee osteoarthritis pain (without diabetes), randomized 1:1:1 to 9mg, 12mg, or placebo over 68 weeks

Adverse Events Relevant to Sexual Function The Phase 2 safety data showed that gastrointestinal adverse events (nausea, vomiting, diarrhea) were the most common treatment-emergent effects, occurring in 70 to 80% of participants at higher doses [1]

Delaying Gastric Emptying : GLP-1 slows down the rate at which the stomach empties its contents, leading to a prolonged feeling of fullness and reduced food intake